The spurious-biomarker pattern: Wright's opsonin index as historical type-specimen
"Fleming thus made a very good living out of selling what were, in effect, sophisticated quack remedies."Wootton, Bad Medicine (Oxford University Press, 2006), p. 244 (on Sir Almroth Wright's Inoculation Department at St Mary's Hospital and Fleming's role in it).
- Bad Medicine: Doctors Doing Harm Since Hippocrates
- The Laboratory as Business: Sir Almroth Wright's Vaccine Programme and the Construction of Penicillin
The spurious-biomarker pattern is the framework with the most direct application to contemporary elite-longevity practice. The pattern’s structural features are: (1) the practitioner or practitioner organization develops or adopts a laboratory measurement whose validity as a surrogate for a hard clinical endpoint is asserted rather than demonstrated; (2) the measurement becomes the operational basis for individualized prescription, repeat consultation, and ongoing treatment monitoring; (3) the measurement’s movement under intervention is then cited as evidence of clinical benefit, in lieu of a hard-endpoint demonstration; (4) the entire commercial practice rests on the cycle of measure, prescribe, re-measure, re-prescribe; (5) attempts to demonstrate that movement on the surrogate corresponds to movement on the hard endpoint are either not undertaken, fail, or are under-powered. The TPE-IVIG protocol’s reliance on epigenetic-clock surrogates (GrimAge, DunedinPACE) for the demonstration of ‘biological-age reversal’ is the archive’s modern type-specimen of the pattern, and is structurally indistinguishable from Wright’s opsonin-index-driven vaccine practice c. 1900 to 1946. The framework’s predictive utility is operational: when a contemporary intervention’s principal evidence base is movement on a proprietary or contested surrogate biomarker, with no published hard-endpoint demonstration and a commercial revenue model that depends on repeat biomarker measurement, the archive’s standing prediction is that the intervention will not, on adequately powered hard-endpoint trial, be shown to extend life or to reduce age-related morbidity beyond placebo. The Chen 1992 chapter, listed here as a source, has not yet been directly read by the archive’s research team; the citation is derived from Wootton’s bibliography and from standard library catalog metadata, and the framework’s reading of the Wright case is gated for independent corroboration on direct reading of Chen.”